Karen C. Dwyer

Learn More
Despite recent advances in the treatment of metastatic melanoma through targeted and immunotherapy, the majority of patients do not achieve a durable response. Research efforts to better understand responses are underway, and numerous molecular mechanisms of resistance to targeted therapy have been identified. There is a growing appreciation of genomic(More)
To enhance the therapeutic index of allogeneic hematopoietic SCT (HSCT), we immunized 10 HLA-matched sibling donors before stem cell collection with recipient-derived clonal myeloma Ig, idiotype (Id), as a tumor antigen, conjugated with keyhole limpet hemocyanin (KLH). Vaccinations were safe in donors and recipients. Donor-derived KLH- and Id-specific(More)
Cancer immune evasion is an emerging hallmark of disease progression. Functional studies to understand the role of myeloid-derived suppressor cells (MDSC) in the tumor microenvironment however, are limited by the lack of available specific cell surface markers. We adapted a competitive peptide phage display platform to identify candidate peptides binding(More)
# These authors contributed equally to this work. Immunotherapy is among the novel classes of therapy in development for acute myeloid leukemia (AML) and harnesses the specificity of the immune system to eliminate leukemia cells. 1 This approach builds upon the success of allogeneic hematopoietic stem cell transplant (allo-SCT) in AML, which can be curative(More)
There have been significant advances in the treatment of melanoma via the use of targeted therapy and immu-notherapy, however a significant proportion of patients still progress on treatment. Intense research efforts are underway to better understand resistance, and multiple molecular resistance mechanisms to targeted therapy have been identified. There is(More)
  • 1